Vasomotor Symptoms Market Share, Trends, Applications and Competitive Landscape Till 2027
Market Highlights
According to MRFR analysis, the
Global Vasomotor Symptoms Market is expected to register a CAGR of
7.27% from 2020 to 2027 and hold a value of USD 8,189 Million
till 2027.
The global Vasomotor Symptoms Market is
driven by several factors, such as rising older female population, rising
initiatives by public and private organizations to create awareness regarding
vasomotor symptoms management options, increasing product launches, and a
number of clinical trials by the prominent players in the market. The
increasing menopausal women also contribute heavily to the growth of this
market. By 2030, the world population of menopausal and postmenopausal women is
projected to increase to 1.2 billion, with 47 million new entrants each year.
A lot of market players are dominating
the global vasomotor symptoms market. The prominent players are involved
in strategic agreements, product launches, and joint ventures to sustain their
market positions. For instance, in October 2018, TherapeuticsMD (US) received
FDA approval for its first bioidentical hormone therapy BIJUVA, a combination
of estradiol and progesterone for moderate to severe vasomotor symptoms
associated with menopause.
Regional Analysis
The market has been divided, by region,
into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The
Americas held the maximum share in 2019, owing to the rise in menopausal women
in the US. For instance, in the US, approximately 1.3 million women become
menopausal each year. The vasomotor symptoms market in the Americas has further
been branched into North America and Latin America, with the North American
market divided into the US and Canada. The European vasomotor symptoms market
has been categorized as Western Europe and Eastern Europe. The Western European
market has further been classified as Germany, France, the UK, Italy, Spain,
and the rest of Western Europe. The European market for vasomotor symptoms is
expected to hold a substantial share owing to the increase in the number of
clinical trials by the prominent players. The vasomotor symptoms market in
Asia-Pacific has been segmented into Japan, China, India, South Korea,
Australia, and the rest of Asia-Pacific. The vasomotor symptoms market in this
region is anticipated to be the fastest-growing during the forecast period due
to the increasing uptake and adoption rate of hormonal therapy. Increasing
patient pool also fuels the market growth. The vasomotor symptoms market in the
Middle East & Africa has been divided into the Middle East and Africa.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/9810
Segmentation
Global Vasomotor Symptoms Market has
been segmented based on the Therapy Type and Distribution Channel.
The market, based on therapy type, has
been segmented into hormonal and non-hormonal. The market, based on hormonal
therapy, has been further divided into estrogen, progesterone, and combination.
The market, based on hormonal therapy, held a major share in 2019 owing to the widespread
use and high preference rate. The market, based on non-hormonal therapy, has
been further divided into antidepressants and others.
The global vasomotor symptoms
market has been segmented, based on distribution channel, into hospital
pharmacies, online stores, and retail pharmacies. The hospital pharmacies
segment held the majority share of the market in 2019 owing to the increasing
number of in-visit patient admissions, whereas the online stores segment is
projected to be the fastest-growing segment during the study period owing to
the increasing preference of this distribution channels owing to the widespread
availability and rise in awareness regarding the e-commerce channels.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/vasomotor-symptoms-market-9810
Key Players
Some of the key players in the
global vasomotor symptoms market are Allergan (Ireland), Pfizer Inc. (US),
Eli Lily and Company (US), Novartis AG (Switzerland), Emcure Pharmaceuticals
Ltd (India), Merck & Co., Inc. (US), TherapeuticsMD, Inc. (US), Mithra
Pharmaceuticals (Belgium), Novo Nordisk A/S (Denmark), Procter & Gamble
(US), EndoCeutics, Inc. (Canada), Amag Pharmaceuticals (US), and Teva
Pharmaceuticals (Israel).
Browse Related Reports at:
Pharmaceutical Robots Market Research Report – Forecast to 2027
Global Cold Pain Therapy Market Research Report - Global Forecast till 2027
Global Ophthalmic Lasers Market Research Report - Global Forecast till 2027
Gel Documentation Systems Market Research Report - Global Forecast till 2027
Blood Screening Market Research Report - Forecast till 2027
About Market Research Future:
At Market Research Future (MRFR), we
enable our customers to unravel the complexity of various industries through
our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), &
Consulting Services. MRFR team have supreme objective to provide the optimum
quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of
Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment